L3VLUP
ProSign in

MEDP · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MEDPJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MEDP
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMEDPJNJ
Q3 202012 holders, $218m30 holders, $26.2bn
Q4 20208 holders, $187m32 holders, $26.6bn
Q1 20219 holders, $153m31 holders, $25.3bn
Q2 20218 holders, $156m37 holders, $25.6bn
Q3 202111 holders, $413m40 holders, $24.1bn
Q4 202112 holders, $668m33 holders, $25.2bn
Q1 20226 holders, $107m35 holders, $28.2bn
Q2 20225 holders, $97m33 holders, $26.9bn
Q3 20223 holders, $59m36 holders, $25.4bn
Q4 202210 holders, $269m35 holders, $27.6bn
Q1 202314 holders, $275m42 holders, $24.5bn
Q2 202317 holders, $468m38 holders, $25.0bn
Q3 202315 holders, $378m37 holders, $18.9bn
Q4 202314 holders, $501m31 holders, $19.0bn
Q1 202417 holders, $1.2bn32 holders, $19.7bn
Q2 202418 holders, $1.3bn35 holders, $20.4bn
Q3 202415 holders, $918m28 holders, $22.3bn
Q4 202415 holders, $1.2bn37 holders, $20.4bn
Q1 202512 holders, $986m32 holders, $20.5bn
Q2 202514 holders, $1.2bn31 holders, $18.4bn
Q3 202517 holders, $1.9bn32 holders, $23.7bn
Q4 202514 holders, $2.1bn29 holders, $27.8bn
Q1 202612 holders, $1.8bn34 holders, $35.6bn
Q2 20269 holders, $2.7bn33 holders, $39.1bn
MEDP

Medpace HLDGS Inc

Holders
9
Reported value
$2.7bn
Buyers
8
Sellers
21

Breadth -13 among 91 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MEDP (3)

Baillie Gifford & Co, PDT Partners LLC, Renaissance Technologies LLC

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →